Enhancing Trafficking of Adoptively Transferred Natural Killer Cells Via Prostaglandin E2 Signaling Folashade Otegbeye, MBChB MPH, Stephen Moreton, Evelyn.

Slides:

Advertisements

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Advertisements

Diagnosis and Management of Acute Closed Angle Glaucoma after Autologous Hematopoietic Stem Cell Transplant Tori Holmes, FNP-BC, Hayley Klein Chopra,

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Development of Pre-Transplant Facesheet for Improved Accuracy of Data Collection through Direct Clinical Oversight Madhu Ragupathi, Jaskiran Kaur, Mostafizur.

Standardized CD3+ Cell Dose for Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT): An Interim Analysis Muhammad Omer Jamil, MD, Ayman Saad, MD,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Eltrombopag Eliminates Transfusion Requirements in a Patient with Fanconi Anemia Ashish Gupta, MD, MPH, Rasmi Palassery, MD, Sanjay Ahuja, MD, MBA, Rachel.

Biology of Blood and Marrow Transplantation

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Treatment of Severe Mucositis Pain with Oral Ketamine Mouthwash

Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis Hyun.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Patient Self-Perceived Burden and Caregiver Burden in Recipients of Hematopoietic Stem Cell Transplantation: A Longitudinal Study Examining Gender Differences

Annelies Billen, Jasmin B. L

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe Shahram.

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Infusion of Autograft Natural Killer Cells/CD14+hla-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Infection Prevention - Visitors and the Best of Intentions

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Comparative Analysis: Trend of Infectious Complications in Cord Blood (CB) Versus Peripheral Blood (PB) and Bone Marrow (BM) Stem Cell Transplant (SCT)

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Hayder Saeed, MD, Michael C

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Development of an Assessment Tool for Patient Evaluation Prior to Hematopoietic Stem Cell Transplantation (HSCT) Jaskiran Kaur, Madhu Ragupathi, Eric.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Does Cryopreserved Hematopoietic Stem Cell Product Need an Expiration Date? Recipients Engrafted Despite Infusion of Products over Five Years in Storage.

Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Mammen Chandy Biology of Blood and Marrow Transplantation

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment Duncan Purtill,

CD137 Expression Identifies Leukemia Specific CTL after in Vitro Priming of Cord Blood T Cells Previously Expanded By CD3/CD28 Co-Stimulation Jeyaraj.

Presentation transcript:

Enhancing Trafficking of Adoptively Transferred Natural Killer Cells Via Prostaglandin E2 Signaling Folashade Otegbeye, MBChB MPH, Stephen Moreton, Evelyn Ojo, Nathan Mackowski, Amar Desai, PhD, Sanford Markowitz, MD PhD, David Wald, MD PhD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S477-S478 (March 2016) DOI: 10.1016/j.bbmt.2015.11.1093 Copyright © 2016 Terms and Conditions

Figure 1 Human NK cell proportion of total cells in mouse circulation 60h post-infusion of 10 × 106 CFSE-labeled NK cells (4 mice/group). NK = untreated NK cells; NAM-NK = NK cells expanded with nicotinamide 5mM; dmPGE-NK = NK cells incubated for 2h with dmPGE2 prior to infusion; SW* = 2mg/kg SW033291 administered q12h pre-NK infusion for 6 doses. Biology of Blood and Marrow Transplantation 2016 22, S477-S478DOI: (10.1016/j.bbmt.2015.11.1093) Copyright © 2016 Terms and Conditions

Figure 2 Human NK cell proportion of total cells in crushed mouse spleen 60h post-infusion of 10 × 106 CFSE-labeled NK cells (4 mice/group). NK = untreated NK cells; NAM-NK = NK cells expanded with nicotinamide 5mM; dmPGE-NK = NK cells incubated for 2h with dmPGE2 prior to infusion; SW* = 2mg/kg SW 033291 administered q12h pre-NK infusion for 6 doses. Biology of Blood and Marrow Transplantation 2016 22, S477-S478DOI: (10.1016/j.bbmt.2015.11.1093) Copyright © 2016 Terms and Conditions

Figure 3 Human NK cell proportion of total cells in mouse bone marrow 60h post-infusion of 10 × 106 CFSE-labeled NK cells (4 mice/group). NK = untreated NK cells; NAM-NK = NK cells expanded with nicotinamide 5mM; dmPGE-NK = NK cells incubated for 2h with dmPGE2 prior to infusion; SW* = 2mg/kg SW 033291 administered q12h pre-NK infusion for 6 doses. Biology of Blood and Marrow Transplantation 2016 22, S477-S478DOI: (10.1016/j.bbmt.2015.11.1093) Copyright © 2016 Terms and Conditions